NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

ImageneBio Stock: Why Analysts See 150% Upside Despite Competitor Setbacks

Leerink rates ImageneBio stock Outperform with $30 target, calling it "undervalued."

ImageneBio Stock: Why Analysts See 150% Upside Despite Competitor Setbacks
Credit: ImageneBio
Already have an account? Sign in.
10/24/2025 · 9:37 AM
IMA
/ Read more

Feed↓

ARS Pharmaceuticals Shares Plunge as Neffy Misses July Insurance Wins
06/25/2026 · 6:54 AM

ARS Pharmaceuticals Shares Plunge as Neffy Misses July Insurance Wins

Despite the setback, Florida Medicaid coverage begins July 1, the company cut 2026 expenses to $248M, and it remains on track for cash-flow breakeven in 2027.

/ Subscriber only
Merck Bolsters Life Sciences Portfolio with $11.3B Bio-Techne Acquisition
Featured/ 06/25/2026 · 6:32 AM

Merck KGaA Bolsters Life Sciences Portfolio with $11.3B Bio-Techne Acquisition

Acquisition of a medical tools maker will be the German group’s biggest in over a decade.

/ Subscriber only
Passage Bio to Merge with Remix Therapeutics in All-Stock Deal, Raises $100 Million
06/24/2026 · 6:04 PM

Passage Bio to Merge with Remix Therapeutics in All-Stock Deal, Raises $100 Million

The combined company will operate as Remix Therapeutics and raised $100M to advance its RNA-targeted pipeline into 2028.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe